<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">7608025</journal-id>
<journal-id journal-id-type="pubmed-jr-id">6790</journal-id>
<journal-id journal-id-type="nlm-ta">Psychopharmacology (Berl)</journal-id>
<journal-id journal-id-type="iso-abbrev">Psychopharmacology (Berl.)</journal-id>
<journal-title-group>
<journal-title>Psychopharmacology</journal-title>
</journal-title-group>
<issn pub-type="ppub">0033-3158</issn>
<issn pub-type="epub">1432-2072</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">28028605</article-id>
<article-id pub-id-type="pmc">5420481</article-id>
<article-id pub-id-type="doi">10.1007/s00213-016-4513-5</article-id>
<article-id pub-id-type="manuscript">NIHMS839537</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Neuropeptide systems and new treatments for nicotine addiction</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Bruijnzeel</surname>
<given-names>Adriaan W.</given-names>
</name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A2">2</xref>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Department of Psychiatry, University of Florida, Gainesville, Florida, USA</aff>
<aff id="A2"><label>2</label>Department of Neuroscience, University of Florida, Gainesville, Florida, USA</aff>
<aff id="A3"><label>3</label>Center for Addiction Research and Education, University of Florida, Gainesville, Florida, USA</aff>
<author-notes>
<corresp id="FN1">Adriaan Bruijnzeel, PhD, University of Florida, Department of Psychiatry, 1149 Newell Dr., Gainesville, Florida 32611, <email>awbruijn@ufl.edu</email>, Telephone: 352-294-4931, Fax: 352-392-9887</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>7</day>
<month>1</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="epub">
<day>28</day>
<month>12</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="ppub">
<month>5</month>
<year>2017</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>5</month>
<year>2018</year>
</pub-date>
<volume>234</volume>
<issue>9-10</issue>
<fpage>1419</fpage>
<lpage>1437</lpage>
<!--elocation-id from pubmed: 10.1007/s00213-016-4513-5-->
<abstract>
<sec id="S1">
<title>RATIONALE</title>
<p id="P1">The mildly euphoric and cognitive enhancing effects of nicotine play a role in the initiation of smoking, while dysphoria and anxiety associated with smoking cessation contribute to relapse. After the acute withdrawal phase, smoking cues, a few cigarettes (i.e., lapse), and stressors can cause relapse. Human and animal studies have shown that neuropeptides play a critical role in nicotine addiction.</p>
</sec>
<sec id="S2">
<title>OBJECTIVES</title>
<p id="P2">The goal of this paper is to describe the role of neuropeptide systems in the initiation of nicotine intake, nicotine withdrawal, and the reinstatement of extinguished nicotine seeking.</p>
</sec>
<sec id="S3">
<title>RESULTS</title>
<p id="P3">The reviewed studies indicate that several drugs that target neuropeptide systems diminish the rewarding effects of nicotine by preventing the activation of dopaminergic systems. Other peptide-based drugs diminish the hyperactivity of brain stress systems and diminish withdrawal-associated symptom severity. Blockade of hypocretin-1 and nociceptin receptors and stimulation of galanin and neurotensin receptors diminishes the rewarding effects of nicotine. Both corticotropin-releasing factor type 1 and kappa-opioid receptor antagonists diminish dysphoria and anxiety-like behavior associated with nicotine withdrawal and inhibit stress-induced reinstatement of nicotine seeking. Furthermore, blockade of vasopressin 1b receptors diminishes dysphoria during nicotine withdrawal and melanocortin 4 receptor blockade prevents stress-induced reinstatement of nicotine seeking. The role of neuropeptide systems in nicotine-primed and cue-induced reinstatement is largely unexplored, but there is evidence for a role of hypocretin-1 receptors in cue-induced reinstatement of nicotine seeking.</p>
</sec>
<sec id="S4">
<title>CONCLUSION</title>
<p id="P4">Drugs that target neuropeptide systems might decrease the euphoric effects of smoking and improve relapse rates by diminishing withdrawal symptoms and improving stress resilience.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Nicotine</kwd>
<kwd>tobacco</kwd>
<kwd>neuropeptide</kwd>
<kwd>CRF</kwd>
<kwd>dynorphin</kwd>
<kwd>hypocretin</kwd>
<kwd>dysphoria</kwd>
<kwd>anxiety</kwd>
<kwd>withdrawal</kwd>
<kwd>relapse</kwd>
</kwd-group>
</article-meta>
</front>
</article>
</pmc-articleset>